News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

Novocure Announces Optune Now Available at more than 150 Leading Cancer Centers across the United States

Al's Comment:

 There are now  over 150 centers certified to use Optune, including some of the best in the world, now making it much easier to find a center close to you  


Posted on: 12/21/2014

19 Dec 2014


Novocure Announces Optune Now Available at more than 150 Leading Cancer Centers across the United States

Novocure™ announcedtoday that more than 150 treatment centers have been certified to prescribeOptune™ to patients with recurrent glioblastoma (GBM).  GBM is the most common form of malignant primarybrain cancer with approximately 10,000 patients diagnosed each year in the US. Thedisease is widely recognized as one of the deadliest forms of cancer and hasvery limited treatment options. TTFields delivered by Optune is the latesttherapy approved by the Food and Drug Administration (FDA) for this hard to treat disease.

Optune is a novel, antimitotic therapy approved in the US for thetreatment of adult patients with recurrent GBM. It is available byprescription from centers whose clinical staffs have been trained to use thesystem. 


Recently trainedtreatment centers and their key contacts include: 

Dana-FarberCancer Institute; David Reardon, MD and Patrick Wen, MD

DukeCancer Institute; Henry Friedman, MD

MayoClinic Cancer Center; Jan Buckner, MD

RoswellPark Cancer Institute; Robert Fenstermaker, MD

StanfordCancer Institute; Seema Nagpal, MD

TexasOncology; Morris Groves, MD

Universityof Texas MD Anderson Cancer Center; Paul Brown, MD


For a complete listof certified treatment centers, please visit http://www.optune.com/find-treament-center. 

“Our goal asclinicians is to treat cancer patients with cutting edge therapies and I ampleased to see that Optune is now so widely available for those patientsfighting recurrent GBM,” said David Reardon, MD, Clinical Director, Center forNeuro-Oncology, Dana-Farber Cancer Institute. 




“We are pleased tooffer Optune to GBM patients at our institution” says Dr. Henry Friedman,Deputy Director, The Preston Robert Tisch Brain Tumor Center at Duke. “We arealso looking forward to potential opportunities to conduct future clinicalresearch with Novocure”. 




“We are honored toadd such a prestigious group of new centers to our current list of certified providers,”said Pritesh Shah, US General Manager. “With the growing body of clinicalevidence and as more physicians gain practical experience with Optune, we havethe opportunity to establish TTFields therapy as a standard-of-care forrecurrent GBM.” 





To read the complete announcement, go to:

http://www.novocure.com/news-and-events/news

 

Click here to unsubscribe or to change your subscriber options.


This service is brought to you by http://www.investis.com

 

 

 

Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740